Our study demonstrates that CSN6‐HMGCS1‐YAP1 pathway is a predictive biomarker in HCC and can be targeted for NAFLD related HCC treatment. This evidence concerns the gene HMGCS1 and metabolic dysfunction-associated steatotic liver disease.